Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Cash & Equivalents (2016 - 2026)

Protara Therapeutics' Cash & Equivalents history spans 14 years, with the latest figure at $14.7 million for Q1 2026.

  • Quarterly Cash & Equivalents fell 83.89% to $14.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Mar 2026, down 83.89% year-over-year, with the annual reading at $49.7 million for FY2025, 69.5% down from the prior year.
  • Cash & Equivalents came in at $14.7 million for Q1 2026, down from $49.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $162.8 million in Q4 2024 to a low of $12.6 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $34.0 million (2023), against an average of $48.0 million.
  • Year-over-year, Cash & Equivalents soared 311.25% in 2024 and then crashed 83.89% in 2026.
  • Protara Therapeutics' Cash & Equivalents stood at $24.1 million in 2022, then skyrocketed by 64.07% to $39.6 million in 2023, then skyrocketed by 311.25% to $162.8 million in 2024, then plummeted by 69.5% to $49.7 million in 2025, then crashed by 70.32% to $14.7 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Cash & Equivalents are $14.7 million (Q1 2026), $49.7 million (Q4 2025), and $12.6 million (Q3 2025).